Last $22.02 USD
Change Today -0.67 / -2.95%
Volume 778.2K
ACAD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 5:20 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

acadia pharmaceuticals inc (ACAD) Snapshot

Open
$22.69
Previous Close
$22.69
Day High
$22.80
Day Low
$21.92
52 Week High
02/28/14 - $32.00
52 Week Low
04/15/14 - $15.64
Market Cap
2.2B
Average Volume 10 Days
829.8K
EPS TTM
$-0.66
Shares Outstanding
99.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACADIA PHARMACEUTICALS INC (ACAD)

acadia pharmaceuticals inc (ACAD) Related Businessweek News

No Related Businessweek News Found

acadia pharmaceuticals inc (ACAD) Details

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson’s disease psychosis, and in Phase II development for Alzheimer’s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

48 Employees
Last Reported Date: 02/27/14
Founded in 1993

acadia pharmaceuticals inc (ACAD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $935.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $605.0K
Vice President, General Counsel, Corporate Co...
Total Annual Compensation: $445.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $178.1K
Compensation as of Fiscal Year 2013.

acadia pharmaceuticals inc (ACAD) Key Developments

ACADIA Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

ACADIA Pharmaceuticals Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $21.5 million, or $0.22 per basic and diluted common share compared to a net loss of $9.1 million, or $0.11 per basic and diluted common share, for the second quarter of 2013. Net losses for the second quarters of 2014 and 2013 included $4.3 million and $1.1 million, respectively, in non-cash, stock-based compensation expense. Collaborative revenues were $28,000 compared to $451,000 a year ago. Loss from operations was $21,723,000 compared to $9,157,000 a year ago. For the six months ended June 30, 2014, the company reported a net loss of $39.3 million, or $0.41 per basic and diluted common share, compared to a net loss of $15.2 million, or $0.19 per basic and diluted common share, for the comparable period of 2013. Net losses for the six-month periods ended June 30, 2014 and 2013 included $7.5 million and $1.6 million, respectively, in non-cash, stock-based compensation expense. Collaborative revenues were $58,000 compared to $868,000 a year ago. Loss from operations was $39,681,000 compared to $15,321,000 a year ago.

ACADIA Pharmaceuticals Inc. to Report Q2, 2014 Results on Aug 05, 2014

ACADIA Pharmaceuticals Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 05, 2014

ACADIA Pharmaceuticals Inc., Q2 2014 Earnings Call, Aug 05, 2014

ACADIA Pharmaceuticals Inc., Q2 2014 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACAD:US $22.02 USD -0.67

ACAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACAD.
View Industry Companies
 

Industry Analysis

ACAD

Industry Average

Valuation ACAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6,708.7x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5,676.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACADIA PHARMACEUTICALS INC, please visit www.acadia-pharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.